The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the US Preventive Services Task Force

C Dubé, A Rostom, G Lewin, A Tsertsvadze… - Annals of internal …, 2007 - acpjournals.org
Background: Aspirin for prevention of colorectal cancer is controversial. Purpose: To
examine the benefits and harms of aspirin chemoprevention. Data Sources: MEDLINE, 1966 …

Extrapolating survival from randomized trials using external data: a review of methods

C Jackson, J Stevens, S Ren, N Latimer… - Medical decision …, 2017 - journals.sagepub.com
This article describes methods used to estimate parameters governing long-term survival, or
times to other events, for health economic models. Specifically, the focus is on methods that …

Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence …

PO Vandvik, AM Lincoff, JM Gore, DD Gutterman… - Chest, 2012 - Elsevier
Background This guideline focuses on long-term administration of antithrombotic drugs
designed for primary and secondary prevention of cardiovascular disease, including two …

Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial

MJ Calvert, N Freemantle, G Yao… - European heart …, 2005 - academic.oup.com
Abstract Aims Whilst the CArdiac REsynchronization in Heart Failure (CARE-HF) trial has
shown that cardiac resynchronization therapy (CRT) leads to reduced morbidity and …

Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events

A Squizzato, M Bellesini, A Takeda… - Cochrane Database …, 2017 - cochranelibrary.com
Background Aspirin is the prophylactic antiplatelet drug of choice for people with
cardiovascular disease. Adding a second antiplatelet drug to aspirin may produce additional …

Clopidogrel: a review of its use in the prevention of thrombosis

GL Plosker, KA Lyseng-Williamson - Drugs, 2007 - Springer
Summary Abstract Clopidogrel (Plavix®, Iscover®) selectively and irreversibly inhibits
adenosine diphosphate (ADP)-induced platelet aggregation. Long-term administration of …

Real-world bleeding in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and prescribed different combinations of …

M Pufulete, J Harris, K Pouwels, BC Reeves… - Open …, 2022 - openheart.bmj.com
Objective To estimate the incidence and HRs for bleeding for different dual antiplatelet
therapies (DAPT) in a real-world population with acute coronary syndrome (ACS) …

CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis

M Jiang, JHS You - Cardiovascular drugs and therapy, 2017 - Springer
Purpose This study aimed to examine the cost-effectiveness of CYP2C19 loss-of-function
and gain-of-function allele guided (LOF/GOF-guided) antiplatelet therapy in patients with …

[HTML][HTML] Carga de enfermedad atribuible al uso de tabaco en Argentina y potencial impacto del aumento de precio a través de impuestos

A Alcaraz, J Caporale, A Bardach… - … de Salud Pública, 2016 - SciELO Public Health
Objetivo Evaluar la carga de enfermedad asociada al consumo de tabaco en Argentina y
estimar el impacto sanitario y económico de aumentos de precio en los cigarrillos a través …

Cost–effectiveness analysis of personalized antiplatelet therapy in patients with acute coronary syndrome

M Jiang, JHS You - Pharmacogenomics, 2016 - Taylor & Francis
Aim: This study aimed to compare the clinical and economic outcomes of pharmacogenetic-
guided (PG-guided) and platelet reactivity testing-guided antiplatelet therapy for patients …